ஐ.எஸ்.எஸ்.என்: 2375-4508
Abha Majumdar* and Poonam Mishra
The outcome of ovulation induction in anovulatory polycystic ovarian syndrome (PCOS) may depend, in part, on the pharmacologic compounds used, but also on individual patient characteristics, such as age, body mass index (BMI), hyper- androgenism, luteinizing hormone (LH), hyper-secretion, anti mullerian hormone (AMH) levels and possibly antral follicle count (AFC) with ovarian volume of these women. There exists a subset of clomiphene citrate (CC) resistant PCOS women who require stimulation of ovulation with high doses of human menopausal gonadotropin (hMG), after not having responded to chronic low dose step up regimes of recombinant follicle stimulating hormone (r-FSH).